Sign in
VTYX Stock Price, Chart, Stats & News
Ventyx Biosciences, Inc.
Save
1.00B
Market cap
–
Current P/E
–
Forward P/E
VTYX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -50.41% |
ROE | -48.11% |
D/E | 0.05x |
Interest coverage ratio | – |
VTYX valuation
P/E | – |
P/S | – |
P/B | 5.22x |
P/CF | -11.38x |
P/FCF | -11.43x |
P/OCF | -11.38x |
PEG | -0.87x |
EV multiple | -9.03x |
About
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.
Similar securities
Based on sector and market capitalization
Report issue